Navigation Links
Quest Diagnostics Reports Second Quarter 2013 Financial Results
Date:7/18/2013

MADISON, N.J., July 18, 2013 /PRNewswire/ --

  • Adjusted diluted EPS from continuing operations of $1.06, vs. $1.15 in 2012
  • Reported diluted EPS from continuing operations of $0.99, vs. $1.09 in 2012
  • Revenues from continuing operations of $1.8 billion, 3.3% below prior year
  • Full year 2013 revenues now expected to be 1% to 2% below prior year
  • Full year 2013 EPS range narrowed to  $4.35 to $4.50
  • Sales of HemoCue and ibrutinib royalty rights for approximately $800 million provide flexibility to drive shareholder value, consistent with our capital deployment strategy
  • Announces new Chief Financial Officer to join company July 29
  • Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that for the second quarter ended June 30, 2013, adjusted income from continuing operations was $164 million, or $1.06 per diluted share, compared to $185 million, or $1.15 per diluted share, for 2012.

    (Logo: http://photos.prnewswire.com/prnh/20130717/NY48934LOGO )

    For the second quarter of 2013, reported income from continuing operations was $153 million, or $0.99 per diluted share, compared to $175 million, or $1.09 per diluted share, in 2012. Income from continuing operations in the second quarter of 2013 was reduced by $12 million, or $0.07 per diluted share, of restructuring and integration costs related to the company's ongoing efforts to drive operational excellence and simplify the organization. In the second quarter of 2012, income from continuing operations was reduced by $0.06 per diluted share related to restructuring, integration and CEO succession costs.

    Revenues from continuing operations were $1.8 billion for the second quarter, 3.3% below the prior year. D
    '/>"/>

    SOURCE Quest Diagnostics Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related biology technology :

    1. Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe
    2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
    3. A 50-year quest to isolate the thermoelectric effect is now over: Magnon drag unveiled
    4. Survey Reveals Paternity Questions Loom for More Than One in 10 Americans
    5. S.E.D. Labs to be Acquired by Quest Diagnostics
    6. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
    7. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
    8. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
    9. Mars, Incorporated Answers Question: How Does Feeding People and Pets Nurture Science and Discovery? At TEDMED 2012
    10. Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrigs Disease)
    11. Questcor Pharmaceuticals Expands Repurchase Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
    (Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
    (Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
    (Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
    Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2
    ... 2, 2011 Quanterix Corporation, a company enabling ... on its revolutionary Si ngle Mo ... the analytical performance of its Prostate Specific Antigen ... 2-log improvement in sensitivity over today,s ultrasensitive third-generation ...
    ... potential drug therapy for a premature ageing disease that affects ... fast as the usual rate. The study is the ... defects in cells and could provide a model for understanding ... could have significant benefits, such as reducing degeneration of some ...
    ... Epitomics, Inc., a California based biotech company, ... of Allowance from the United States Patent and ... Expressed Proteins (application 10/705,109).  The Notice allowed 17 ... cell samples using libraries of antibodies.  This method ...
    Cached Biology Technology:Quanterix Fifth-Generation PSA Test Enables More Sensitive Measurements Following Surgery 2Cellular repair could reduce premature aging 2Cellular repair could reduce premature aging 3
    (Date:10/15/2014)... Oct. 15, 2014 Sandata Technologies, LLC, ... and community-based care, today announced it released a ... Santrax® Electronic Visit Verification™ Solution (EVV™)  for Quality ... home health company founded in 1996 and has ... The study details the challenges ...
    (Date:10/15/2014)... German Gauß-Allianz has admitted Johannes Gutenberg University Mainz ... Rhineland-Palatinate science hub continues to maintain a significant ... , "The acceptance of Johannes Gutenberg University ... is a milestone in the national and international ... The state of Rhineland-Palatinate can be proud that ...
    (Date:10/15/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" ... mobile commerce market releases photos and video of the recent opening ... 13 th . Gino Pereira , CEO ... investor Mr. Chad A. Verdi rang the bell.  ... investors and employees "for their work and dedication in bringing the ...
    Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
    ... electronic system that stimulates the nerve of the diaphragm muscles ... for use in patients with Amyotrophic Lateral Sclerosis (ALS), also ... Diaphragm Pacing System (DPS) will help ALS patients breathe longer ... the surgeon at University Hospitals (UH) Case Medical Center who ...
    ... Most drug therapy interventions for people with autism have ... Now, University of Missouri researchers are examining the use ... pressure and control heart rate as well as to ... with autism difficulty with normal social skills, language ...
    ... available in German . , London. The global uptake ... cent more than previously thought. This is the conclusion of an ... atoms in the carbon dioxide of the atmosphere driven by the ... converted faster than expected during the El Nio years, current estimates ...
    Cached Biology News:Diaphragm pacing system receives FDA approval for use with ALS patients 2Study finds promising drug treatment for improving language, social function in people with autism 2Productivity of land plants may be greater than previously thought 2Productivity of land plants may be greater than previously thought 3
    ... 97 Cytological Labeling Kit provides a unique ... of cellular targets, including cell-surface receptors and ... Kit contains the patented ELF 97 phosphatase ... precipitate at the site of enzymatic activity ...
    ... between the various commercial and lab-prepared glass ... the length and GC content of the ... protocol employed all influence the optimal hybridization ... all the different variables to consider, it ...
    ... Stain combo offers these benefits: ... Offers a safer and ... Eliminates risks to yourself, the environment and your ... bp to >30 kb. UltraPure Agarose is a standard ...
    This is a PYREX replacement Allihn condenser with a 34/45 inner joint on the bottom for the No. CLS3840-S 125mL extractor system. The tubulation O.D. on the condenser is 10mm....
    Biology Products: